Orforglipron for adults who are overweight and at risk of obesity-related health problems
Tests orforglipron against placebo in adults who are overweight.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Key facts
- Where
- Buenos Aires, CABA, Ciudad de Buenos Aires, Esperanza, Lanus, Mar del Plata, Mendoza, Rosario, San Isidro, SAN M. de Tucuman, San Nicolás de los Arroyos, and Santa Fe, ArgentinaSee the 20 sites
- Phase
- Phase 3
Where in Argentina
- CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaNot yet recruiting
- CEMEDICBuenos Aires, ArgentinaTaking people
- Centro Médico ViamonteBuenos Aires, ArgentinaNot yet recruiting
- CIPRECBuenos Aires, ArgentinaNot yet recruiting
- CONEXA Investigacion Clinica S.A.Buenos Aires, ArgentinaTaking people
- Fundacion RespirarBuenos Aires, ArgentinaNot yet recruiting
- Investigaciones Medicas Imoba SrlBuenos Aires, ArgentinaNot yet recruiting
- Instituto CentenarioCABA, ArgentinaTaking people
- IDIM - Instituto de Investigaciones MetabólicasCiudad de Buenos Aires, ArgentinaTaking people
- Sanatorio EsperanzaEsperanza, ArgentinaNot yet recruiting
- Centro Diagnóstico BioimagenesLanus, ArgentinaNot yet recruiting
- Centro de Investigaciones Medicas Mar Del PlataMar del Plata, ArgentinaNot yet recruiting
- Instituto de Cardiología WolffMendoza, ArgentinaTaking people
- Instituto de Investigaciones Clinicas RosarioRosario, ArgentinaNot yet recruiting
- Instituto Especialidades de la Salud RosarioRosario, ArgentinaTaking people
- CardioAlem InvestigacionesSan Isidro, ArgentinaNot yet recruiting
- Instituto Médico de Alta Complejidad San Isidro SaSan Isidro, ArgentinaNot yet recruiting
- Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaTaking people
- Instituto de Investigaciones Clínicas San NicolasSan Nicolás de los Arroyos, ArgentinaNot yet recruiting
- Centro de Investigaciones Clinicas del LitoralSanta Fe, ArgentinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07794579EU 2026-526175-35-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.Read full original descriptionShow less
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Inclusion: Have an increased waist-to-height ratio of ≥0.5; Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia); Have at least one unsuccessful attempt to reduce body weight based on diet and exercise; Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds.
Exclusion: Do not have a stable body weight within 90 days before screening; Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening; Have a prior or planned surgical treatment or procedure for obesity; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold); Have hypertension or history of hypertension; Have dyslipidemia or history of dyslipidemia.